Wegovy side effects, honestly listed.

The most serious potential side effects of Wegovy are rare but include acute pancreatitis (severe abdominal pain radiating to the back), gallbladder disease, acute kidney injury from dehydration caused by vomiting or diarrhea, severe allergic reactions, and diabetic retinopathy complications in people with pre-existing diabetes. Wegovy also carries a boxed warning for thyroid C-cell tumors based on rodent studies; the human risk is unknown but the drug is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.

Most gastrointestinal side effects — nausea, diarrhea, constipation, reflux — are mild to moderate and resolve within a few days to a few weeks. They are most intense during the first week after a dose increase and typically fade as your body adjusts. For most patients they settle down significantly after the titration period (the first 4-5 months). A small percentage of people continue to experience mild nausea throughout maintenance.

Hair loss was reported by about 3% of Wegovy users in clinical trials, compared to 1% in the placebo group. It is generally diffuse thinning (telogen effluvium) rather than patchy loss, and is thought to be triggered by the rapid weight loss itself rather than a direct drug effect. Most cases resolve after weight loss stabilizes. Ensuring adequate protein intake (at least 60-80 g per day) and checking iron, vitamin D, and zinc levels may help.

Fatigue was reported in about 11% of people taking Wegovy in clinical trials, compared to 4% on placebo. It is most common during dose escalation and usually improves within weeks. Common causes include reduced calorie intake (especially carbohydrates), mild dehydration from GI symptoms, and low blood sugar in people also taking diabetes medications. Staying hydrated, eating small balanced meals, and prioritizing sleep usually help.

Most people notice mild GI symptoms within 1 to 3 days of their first injection. Nausea tends to peak in the first week after a dose increase and then gradually improves. Because the drug has a half-life of about a week, some patients feel worse on the day of injection or the day after, then better through the rest of the week. Side effects often flare up again briefly each time the dose is escalated during the titration schedule.

There is no absolute prohibition, but most providers recommend limiting alcohol on Wegovy for several reasons. Semaglutide slows gastric emptying, which can make alcohol absorption unpredictable and intensify intoxication and hangovers. Alcohol can also worsen nausea, acid reflux, and dehydration — side effects that Wegovy can already cause. It may also irritate the pancreas, and pancreatitis is a rare but serious Wegovy side effect. Many Wegovy users actually report reduced alcohol cravings as a surprise benefit, a phenomenon under active clinical investigation.

As of 2026, the longest published clinical trial data covers about two years of continuous use. The SELECT cardiovascular outcomes trial followed more than 17,000 patients on semaglutide for up to five years and showed a 20% reduction in major adverse cardiovascular events without new safety signals. Real-world post-marketing surveillance since 2021 has not identified unexpected long-term risks, though regulatory agencies continue to monitor rare events such as gastroparesis, suicidal ideation (not confirmed to be caused by the drug), and vision changes in diabetics.

Yes — sulfur-smelling burps (dysgeusia and eructation) are a known but uncommon side effect of GLP-1 medications including Wegovy. They are caused by delayed gastric emptying that allows food to linger in the stomach longer, producing hydrogen sulfide gas during partial digestion. They are not dangerous and can often be reduced by eating smaller meals, avoiding high-sulfur foods (eggs, broccoli, garlic, red meat), staying upright for 30 minutes after eating, and limiting fatty or spicy foods during the first weeks after each dose increase.

If you miss a dose and your next scheduled dose is more than 48 hours away, take the missed dose as soon as you remember. If your next scheduled dose is less than 48 hours away, skip the missed dose and take your next dose on the regular day. Never take two doses at the same time to "catch up". If you miss doses for more than two weeks, contact your provider — you may need to restart at a lower dose to avoid intensified side effects.

Pancreatitis is listed in the Wegovy prescribing information as an uncommon but serious side effect. In clinical trials, acute pancreatitis occurred in about 0.2% of Wegovy users, which is similar to the background rate in the general population. Post-marketing reports have identified cases, so the FDA-required label warns providers to watch for it. Severe, persistent abdominal pain — especially pain that radiates to the back, may be accompanied by nausea and vomiting, and worsens with eating — warrants immediate medical attention.

"Wegovy face" refers to the loss of facial volume and increased wrinkling that some people notice with rapid weight loss. It is not a direct drug effect — it is the normal consequence of losing subcutaneous fat in the cheeks and temples, which happens with any significant weight loss. Slower weight loss (staying on lower doses longer), adequate protein intake to preserve muscle, resistance training, and good hydration can all help minimize the appearance. For some people, dermatology treatments may be appropriate once weight stabilizes.

The FDA label carries a boxed warning based on rodent studies in which semaglutide caused thyroid C-cell tumors. It is unknown whether this translates to humans, and large clinical trials have not shown an increased rate of thyroid cancer in people taking semaglutide. As a precaution, Wegovy is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2). Patients should report any neck lump, hoarseness, difficulty swallowing, or persistent throat discomfort.

There are no Wegovy side effects that occur exclusively in women, but several are reported more often by female patients: hair loss (thought to be related to rapid weight loss rather than a hormonal effect), changes to the menstrual cycle (usually improvements in cycles disrupted by polycystic ovary syndrome), and reduced effectiveness of oral contraceptives in the first weeks after a dose increase due to delayed gastric absorption. Wegovy should not be used during pregnancy or breastfeeding. Women who could become pregnant should use reliable contraception and stop Wegovy at least two months before a planned pregnancy.